Investigators have recently proposed that the accumulation of neoantigens could make AML with spliceosome mutations more responsive to antibodies against programmed cell death 1 (PD-1) or its ligand (PD-L1) [37]. Here, PDCD1 is linked to acute myeloid leukemia.